PeptidePro-apoptotic peptideAnti-obesity experimentalHoming peptide

Adipotide (FTPP)

Also known as FTPP · Prohibitin-targeting peptide-1 · CKGGRAKDC-GG-D(KLAKLAK)2

Written by enwyReviewed 5 Aug 20261 sources0 comments

An experimental pro-apoptotic peptide (a homing sequence fused to a mitochondrial-disrupting KLA motif) designed to selectively kill the blood vessels feeding white adipose tissue, causing fat loss. Demonstrated weight loss in obese primates, but with dose-limiting kidney toxicity and no completed human efficacy trials.

01 Overview

Adipotide (also written FTPP / prohibitin-targeting peptide) couples a peptide that homes to prohibitin on adipose vasculature with a pro-apoptotic KLA sequence that disrupts mitochondrial membranes in the targeted endothelial cells. Destroying the fat tissue's blood supply drove marked, rapid weight loss in obese rhesus monkeys.

The same mechanism produced renal toxicity in primate studies, a key reason it has not advanced to established human use. It is sold on the grey market for fat loss well beyond any safety evidence; the closely related bare slug 'adipotide' already exists in this database and this entry covers the FTPP-designated variant.

02 Mechanism

A prohibitin-homing peptide fused to a KLA pro-apoptotic motif that selectively induces apoptosis in the endothelium supplying white adipose tissue, ablating its blood supply.

03 Dosing

Tier	Dose	Route	Notes
Primate-derived (extrapolated)	0.4 mg/kg/day	SubQ	Approximate primate study dosing; no validated human dose. Nephrotoxicity is dose-limiting.

04 Effects

Effect	Magnitude	Evidence
Rapid fat lossMarked weight and fat reduction in obese monkeys via targeted destruction of adipose vasculature.	~11% weight loss in obese primates	Preclinical
Improved metabolic markersAccompanying improvements in metabolic parameters in animal studies.	Better insulin sensitivity (primates)	Preclinical

05 Side effects

Effect	Severity	Frequency	Evidence	Countermeasures
NephrotoxicityDose-dependent kidney injury observed in primate studies, the main barrier to development.	Severe	Dose-limiting	Preclinical
Unknown human safetyNo completed human efficacy or safety trials despite grey-market fat-loss marketing.	Severe	Unknown	Unconfirmed

06 Legal status

United States

Research chemical

Not approved; sold 'for research use only'. · as of Jan 2026

07 References

A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeysSci Transl Med, 2011

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.